Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 01/17 10:00:00 pm
102.02 USD   -2.67%
01/17 CELGENE : Juno Therapautics Pops on Word of Buyout by Celgene
01/17 JUNO THERAPEUTI : up on Celgene takeout rumors
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about CELGENE CORPORATION
01/17 CELGENE : Juno Therapautics Pops on Word of Buyout by Celgene
01/17 JUNO THERAPEUTICS : up on Celgene takeout rumors
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/09 U.S. pharma executives expect deals to pick up after tax overhaul
01/08 Celgene, Dave & Buster's slide while Kohl's and Crocs rise
01/08 Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid
01/08 CELGENE CORPORATION (NASDAQ : CELG) Files An 8-K Results of Operations and Finan..
01/08 CELGENE CORPORATION : Announces Preliminary 2017 Unaudited Results and 2018 Fina..
01/08 $11 billion biotech binge fuels forecasts of 2018 M&A surge
01/08 CELGENE : buys cancer therapy maker Impact Biomedicines for $1.1B
01/08 CELGENE CORPORATION (NASDAQ : CELG) Kicks Off J.P. Morgan With A Bang
01/08 Celgene gets JAK-2 inhibitor in Impact deal
01/08 CELGENE : CELG Makes Blockbuster Purchase, MDXG, NBIX On Watch, Busy Year Ahead ..
More most relevant news
All news about CELGENE CORPORATION
01/17 CELGENE : Juno Therapautics Pops on Word of Buyout by Celgene
01/17 JUNO THERAPEUTICS : up on Celgene takeout rumors
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/14 Drug innovations helping cancer patients worldwide
01/10 CELGENE : J.P. Morgan kicks off with a deal as Celgene pays $1.1B for Impact Bio..
01/10 CELGENE : expects 2018 growth as it moves past setbacks that cratered shares
01/09 U.S. pharma executives expect deals to pick up after tax overhaul
01/09 CELGENE : buys cancer therapy maker Impact Biomedicines for $1.1B
More news
Sector news : Pharmaceuticals - NEC
01/17 TSX ends up as banks lead rally after rate hike
01/17 ASPEN PHARMACARE : Drugmaker GSK cuts back in Africa to hone emerging markets mo..
01/17 EXCLUSIVE : J&J attracts Chinese interest for diabetes business in potential $3-..
01/17 Allergan Pact Advances -- WSJ
01/17 Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareh..
01/16 Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareh..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/17 HEALTHCARE : The 'Week That Was' Was Good
01/17 Celgene slips 2% premarket on potential Juno takeout
01/17 Juno rally spreads to bluebird and Cellectis
01/17 WALL STREET BREAKFAST : Investors Ready For Fed-Filled Day
01/17 POLEN CAPITAL : Portfolio Manager Commentary Q4 2017
01/17 U.S. BIOTECH/PHARMA SECTOR DAILY OBS : January 16, 2018
Latest Tweets
05:19a? Monthly Subscription - Mid-Week Review VIDEO 1/18 $SPY $ES_F $VIX $IWM $Q..
1
05:18a? À La Carte - Mid-Week Review VIDEO 1/18: $SPY $ES_F $VIX $IWM $QQQ $BA $I.. 
05:08a? Mid-Week Review VIDEO 1/18: $SPY $ES_F $VIX $IWM $QQQ $BA $IBM $XBT $GBTC.. 
04:22aA Match Made in Heaven? Why a Celgene-Juno Deal Makes ‘Perfect Sense’ https:..
2
03:53aApparently Celgene heard investor complaints about the paltry size of its las..
1
More tweets
Qtime:487
Financials ($)
Sales 2017 12 978 M
EBIT 2017 7 488 M
Net income 2017 4 448 M
Debt 2017 4 449 M
Yield 2017 -
P/E ratio 2017 18,79
P/E ratio 2018 14,69
EV / Sales 2017 6,70x
EV / Sales 2018 5,53x
Capitalization 82 527 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 124 $
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION0.44%82 527
JOHNSON & JOHNSON4.32%394 542
NOVARTIS1.41%227 089
PFIZER0.88%218 162
ROCHE HOLDING LTD.-4.26%211 361
MERCK AND COMPANY10.31%169 287